(Q33750231)

29 July 2017

title

The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial (English)

1 reference

multicenter clinical trial

29 July 2017

main subject

0 references

sepsis

0 references

author name string

Jianfeng Wu

1

1 reference

29 July 2017

Lixin Zhou

2

1 reference

29 July 2017

Jiyun Liu

3

1 reference

29 July 2017

Gang Ma

4

1 reference

29 July 2017

Qiuye Kou

5

1 reference

29 July 2017

Zhijie He

6

1 reference

29 July 2017

Juan Chen

7

1 reference

29 July 2017

Bin Ou-Yang

8

1 reference

29 July 2017

Minying Chen

9

1 reference

29 July 2017

Yinan Li

10

1 reference

29 July 2017

Xiaoqin Wu

11

1 reference

29 July 2017

Baochun Gu

12

1 reference

29 July 2017

Lei Chen

13

1 reference

29 July 2017

Zijun Zou

14

1 reference

29 July 2017

Xinhua Qiang

15

1 reference

29 July 2017

Yuanyuan Chen

16

1 reference

29 July 2017

Aihua Lin

17

1 reference

29 July 2017

Guanrong Zhang

18

1 reference

29 July 2017

Xiangdong Guan

19

1 reference

29 July 2017

publication date

17 January 2013

1 reference

29 July 2017

1 reference

29 July 2017

volume

17

1 reference

29 July 2017

issue

1

1 reference

29 July 2017

page(s)

R8

1 reference

A clinical trial to maintain glycemic control in youth with type 2 diabetes

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Changes of monocyte human leukocyte antigen-DR expression as a reliable predictor of mortality in severe sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Immunotherapy for sepsis--a new approach against an ancient foe.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Thymosin alpha 1: past clinical experience and future promise

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Thymosin alpha1: the regulator of regulators?

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Deaths: final data for 2006.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

A prospective, observational registry of patients with severe sepsis: the Canadian Sepsis Treatment and Response Registry

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Intensive insulin therapy and pentastarch resuscitation in severe sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Monitoring immune dysfunctions in the septic patient: a new skin for the old ceremony

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

The pathophysiology and treatment of sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Allocation concealment in randomised trials: defending against deciphering

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Purification and Biological Activity of Thymosin, a Hormone of the Thymus Gland

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Characterization of the immunoregulatory properties of thymosin alpha 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units.

21 June 2018

1 reference

Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis.

21 January 2018

1 reference

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

21 January 2018

1 reference

Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling

21 January 2018

1 reference

Monocytic HLA-DR expression in intensive care patients: interest for prognosis and secondary infection prediction

21 January 2018

1 reference

Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria

21 January 2018

1 reference

Early prognosis in severe sepsis via analyzing the monocyte immunophenotype

21 January 2018

1 reference

Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.

21 January 2018

1 reference

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

21 January 2018

1 reference

Drotrecogin alfa (activated) in adults with septic shock.

21 January 2018

1 reference

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

Measurement of monocytic HLA-DR (mHLA-DR) expression in patients with severe sepsis and septic shock: assessment of immune organ failure

21 January 2018

1 reference

Treatment of patients with severe sepsis using ulinastatin and thymosin alpha1: a prospective, randomized, controlled pilot study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

A new immunomodulatory therapy for severe sepsis: Ulinastatin Plus Thymosin {alpha} 1.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4056079

Thymosin 1 activates the TLR9/MyD88/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo

30 October 2018

1 reference

Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock

21 January 2018

1 reference

12 December 2020

[Clinical study and long-term evaluation of immunomodulation therapy on trauma, severe sepsis and multiple organ dysfunction syndrome patients]

1 reference

12 December 2020

Pathophysiology of sepsis

1 reference

12 December 2020

[Clinical trial with a new immunomodulatory strategy: treatment of severe sepsis with Ulinastatin and Maipuxin]

1 reference

12 December 2020

Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China

1 reference

12 December 2020

From lab to bedside: emerging clinical applications of thymosin α1

1 reference

12 December 2020

Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study

1 reference

12 December 2020

EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units

1 reference

12 December 2020

Monocyte deactivation in septic patients: restoration by IFN-gamma treatment

1 reference

12 December 2020

Changes in blood lymphocyte populations after multiple trauma: association with posttraumatic complications

1 reference

12 December 2020

Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones

1 reference

12 December 2020

Identifiers

DOI

10.1186/CC11932

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference